J&J beats in Q4 with in line guidance; so why is its stock falling?

Johnson & Johnson (NYSE:JNJ) fell ~3% in early trading on Wednesday, marking its biggest intraday drop since July 2023, even as the healthcare giant posted better-than-expected financials for Q4 2024 with an in-line earnings outlook for 2025.

While the company’s